Report: Jurickson Profar agrees to 3-year, $21M deal with Padres

Kyle Terada-USA TODAY Sports
0 Comments

NEW YORK — Jurickson Profar is staying with the San Diego Padres, agreeing to a three-year, $21 million contract, a person familiar with the negotiations told The Associated Press.

The person spoke on condition of anonymity Friday because the agreement is subject to a successful physical.

Profar, who turns 28 on Feb. 20, was acquired by San Diego from Oakland in December 2019 and hit a career-best .278 in the pandemic-shortened season with seven homers and 25 RBIs. He mostly split time at second base and left field but also played two games in right field and one each in center and at first base.

He earned $2,111,111 in prorated pay from a $5.7 million salary.

Profar has a .238 average with 59 homers and 222 RBIs in seven major league seasons with Texas (2012-13, 2016-18), Oakland (2019) and San Diego. He missed 2014 and 2015 due to a shoulder injury.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.